Target Price | $253.00 |
Price | $254.14 |
Deviation | 0.45% |
Number of Estimates | 16 |
16 Analysts have issued a price target IBM 2026 . The average IBM target price is $253.00. This is 0.45% lower than the current stock price. The highest price target is $300.00 18.05% , the lowest is $170.00 33.11% . | |
A rating was issued by 22 analysts: 11 Analysts recommend IBM to buy, 8 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IBM stock has an average upside potential 2026 of 0.45% . Most analysts recommend the IBM stock at Purchase. |
16 Analysts have issued a sales forecast IBM 2025 . The average IBM sales estimate is $66.2b . This is 5.39% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $66.8b 6.26% , the lowest is $64.9b 3.33% .
This results in the following potential growth metrics:
2024 | $62.8b | 1.44% |
---|---|---|
2025 | $66.2b | 5.53% |
2026 | $69.1b | 4.37% |
2027 | $72.1b | 4.27% |
2028 | $74.1b | 2.78% |
2029 | $77.8b | 4.96% |
11 Analysts have issued an IBM EBITDA forecast 2025. The average IBM EBITDA estimate is $17.3b . This is 8.92% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $18.8b 18.59% , the lowest is $14.8b 6.71% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $15.4b | 3.11% |
---|---|---|
2025 | $17.3b | 12.37% |
2026 | $18.4b | 6.39% |
2027 | $19.0b | 3.62% |
2028 | $16.2b | 15.10% |
2029 | $17.4b | 7.40% |
2024 | 24.48% | 1.65% |
---|---|---|
2025 | 26.07% | 6.49% |
2026 | 26.57% | 1.92% |
2027 | 26.41% | 0.60% |
2028 | 21.81% | 17.42% |
2029 | 22.32% | 2.34% |
6 IBM Analysts have issued a net profit forecast 2025. The average IBM net profit estimate is $8.6b . This is 58.38% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $9.2b 69.54% , the lowest is $8.0b 48.19% .
This results in the following potential growth metrics and future Net Margins:
2024 | $6.0b | 21.01% |
---|---|---|
2025 | $8.6b | 43.11% |
2026 | $9.2b | 8.13% |
2027 | $9.7b | 5.18% |
2028 | $9.8b | 1.19% |
2029 | $11.0b | 12.18% |
2024 | 9.52% | 22.13% |
---|---|---|
2025 | 12.91% | 35.56% |
2026 | 13.38% | 3.64% |
2027 | 13.49% | 0.82% |
2028 | 13.29% | 1.48% |
2029 | 14.20% | 6.85% |
6 Analysts have issued a IBM forecast for earnings per share. The average IBM EPS is $9.20 . This is 58.35% higher than earnings per share in the financial year 2024. The highest EPS forecast is $9.85 69.54% , the lowest is $8.61 48.19% .
This results in the following potential growth metrics and future valuations:
2024 | $6.43 | 21.01% |
---|---|---|
2025 | $9.20 | 43.08% |
2026 | $9.95 | 8.15% |
2027 | $10.47 | 5.23% |
2028 | $10.59 | 1.15% |
2029 | $11.88 | 12.18% |
Current | 43.72 | 133.05% |
---|---|---|
2025 | 27.62 | 36.83% |
2026 | 25.54 | 7.53% |
2027 | 24.28 | 4.93% |
2028 | 24.00 | 1.15% |
2029 | 21.39 | 10.88% |
Based on analysts' sales estimates for 2025, the IBM stock is valued at an EV/Sales of 4.31 and an P/S ratio of 3.57 .
This results in the following potential growth metrics and future valuations:
Current | 4.54 | 43.67% |
---|---|---|
2025 | 4.31 | 5.04% |
2026 | 4.13 | 4.19% |
2027 | 3.96 | 4.10% |
2028 | 3.85 | 2.71% |
2029 | 3.67 | 4.73% |
Current | 3.76 | 53.28% |
---|---|---|
2025 | 3.57 | 5.12% |
2026 | 3.42 | 4.19% |
2027 | 3.28 | 4.10% |
2028 | 3.19 | 2.71% |
2029 | 3.04 | 4.73% |
Analyst | Rating | Action | Date |
---|---|---|---|
Wedbush |
Outperform
➜
Outperform
|
Unchanged | May 07 2025 |
UBS |
Sell
➜
Sell
|
Unchanged | Apr 24 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 24 2025 |
Wedbush |
Outperform
➜
Outperform
|
Unchanged | Apr 24 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 14 2025 |
Jefferies |
Hold
➜
Hold
|
Unchanged | Mar 31 2025 |
Oppenheimer |
➜
Outperform
|
Initiated | Feb 11 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Wedbush:
Outperform
➜
Outperform
|
May 07 2025 |
Unchanged
UBS:
Sell
➜
Sell
|
Apr 24 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Apr 24 2025 |
Unchanged
Wedbush:
Outperform
➜
Outperform
|
Apr 24 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 14 2025 |
Unchanged
Jefferies:
Hold
➜
Hold
|
Mar 31 2025 |
Initiated
Oppenheimer:
➜
Outperform
|
Feb 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.